SLC5A2 and hydrops fetalis: Similarly, for the HF hospitalization outcome in patients with STEMI, SGLT2 inhibitors had no significant effect compared with placebo (RR: 0.85; 95% CI 0.64, 1.12; I2 = 0%; Supplementary Fig. 9B).